-
1دورية أكاديمية
المؤلفون: Makimoto, Go, Misawa, Mahito, Maeda, Yoshinobu, Kiura, Katsuyuki
المصدر: Respiratory Medicine Case Reports
مصطلحات موضوعية: Chronic myeloid leukemia, Chylothorax, Dasatinib
الوصف: Dasatinib, an effective second-generation tyrosine kinase inhibitor, is used to treat breakpoint cluster region-Ableson-positive chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphocytic leukemia. One common adverse event associated with dasatinib use is fluid retention, including pleural effusion. Chylothorax, however, is a rare adverse event. Although the precise mechanism of dasatinib-induced chylothorax is unclear, almost all cases involve right or bilateral chylothorax, and mostly occur within 5 years of dasatinib initiation. Here, we report a rare case of a patient with dasatinib-induced massive left chylothorax 10 years after dasatinib initiation, which improved after dasatinib termination and a switch to bosutinib.
العلاقة: info:pmid/35585905; https://ousar.lib.okayama-u.ac.jp/files/public/6/63708/20220621164238889332/fulltext.pdfTest; https://ousar.lib.okayama-u.ac.jp/63708Test
-
2دورية أكاديمية
المؤلفون: Sakamoto, Yuichi, Mariya, Yasushi, Oshikiri, Toshiyuki, Sasaki, Sumiko, Segawa, Megumi, Teshiromori, Ryuichi, Ogura, Kazuto, Akagi, Tomoaki, Kaimori, Mitsuomi, Kubo, Kohmei
المصدر: Acta Medica Okayama
مصطلحات موضوعية: chronic myeloid leukemia (CML), BCR-ABL, minimal residual disease (MRD), imatinib mesylate, real-time quantitative PCR (RQ-PCR)
الوصف: Chronic myeloid leukemia (CML) is caused by the BCR-ABL oncogene. The Philadelphia chromosome (Ph) from a reciprocal translocation, t(9;22) (q34;q11) causes a fusion gene, BCR-ABL, that encodes a constitutively active tyrosine kinase. Treatment of CML by imatinib is effective to control the tyrosyl phosphorylation of the protein related to the cell signaling. BCR-ABL mRNA is overexpressed in the minimal residual disease (MRD), known as an early sign of relapse. Between December 2005 and June 2008, we measured BCR-ABL mRNA levels in the bone marrow (BM) from patients by quantitative real-time polymerase chain reaction (RQ-PCR) in Aomori Prefectural Central Hospital. Eighty-six samples from 26 patients were collected. Among the 26 CML patients, 11 patients (42%) were in the pretreatment group. Seven (64%) of the 11 patients achieved complete molecular response (CMR). In the post-treatment group consisting of the remaining 15 patients, 9 (60%) patients achieved CMR. The patients receiving imatinib at a dose over 300mg per day required 13 (6-77) months [median (range)] to achieve CMR. On the other hand, the patients receiving a dose below 300mg per day required 29.5 (11-84) months [median (range)]. When BCR-ABL mRNA was detected during the treatment course of patients with CMR, careful observation of BCR-ABL mRNA was useful for tracking the clinical course of patients. In conclusion, the BCR-ABL mRNA level was useful for monitoring the clinical course in 26 patients with CML.
العلاقة: info:pmid/22037271; https://ousar.lib.okayama-u.ac.jp/files/public/4/47016/20160528085747907652/65_5_335.pdfTest; AA00508441; https://ousar.lib.okayama-u.ac.jp/47016Test
الإتاحة: https://doi.org/10.18926/AMO/47016Test
https://ousar.lib.okayama-u.ac.jp/files/public/4/47016/20160528085747907652/65_5_335.pdfTest
https://ousar.lib.okayama-u.ac.jp/47016Test -
3رسالة جامعية
المؤلفون: Masuda, Kozo
مصطلحات موضوعية: REVERSE-TRANSCRIPTASE, HISTOCOMPATIBILITY LEUKOCYTE ANTIGEN, TELOMERASE, CHRONIC MYELOID-LEUKEMIA, CYTOTOXIC T-LYMPHOCYTES, TUMOR-CELL LINES, HAPLOTYPE LOSS, LARYNGEAL CARCINOMAS, GENETIC ALTERATIONS, SURFACE EXPRESSION, CERVICAL-CANCER
الوصف: Loss or down-regulation of human leukocyte antigen (HLA) class I expression has been demonstrated in a variety of solid tumors. To date, such altered HLA expression has not been studied extensively in freshly isolated leukemic blasts. If it occurs, leukemic cells could escape T-cell surveillance as a consequence. Genotypes of nine leukemic cell lines were determined using a polymerase chain reaction for HLA classes I and II. Cells were also examined for HLA beta2-microglobulin, and allele-specific HLA protein expression using flow cytometry. Next, 44 samples of freshly isolated leukemic blasts from 43 patients with malignant hematological diseases were examined for allele-specific HLA expression using flow cytometry. Microsatellite analysis was performed to determine heterozygosity in the HLA region on chromosome 6. Genotype analysis for HLA class I together with microsatellite analysis demonstrated loss of HLA haplotype in HL-60 cells. No loss of HLA haplotype was observed in 44 samples of freshly isolated leukemic blasts. As reported previously, flow cytometric analysis rarely demonstrated loss or down-regulation of HLA expression at initial diagnosis (3/39; 7.7%); however, this was evident in two of five cases in relapse (40.0%), which contrasts with previous reports. In one patient with acute leukemia, HLA-A2 cell surface expression was present at initial diagnosis, lost at relapse, and completely restored after 48 h of culture in the presence of interferon-gamma. These results suggest loss of allele-specific HLA expression may be involved in the pathogenesis of relapse in patients with leukemia. The findings should be valuable in designing new strategies for clinical immunotherapy.
العلاقة: https://ousar.lib.okayama-u.ac.jp/files/public/1/11720/20160527190041879432/K003313.pdfTest; https://ousar.lib.okayama-u.ac.jp/11720Test
النص الكامل